Search clinical trials for: Laquinimod

Total 36 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

Multiple Sclerosis

United States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod (LEGATO-HD)

Huntington's Disease

United States, Canada, Czechia, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Laquinimod Phase IIa Study in Active Crohn's Disease

Crohn's Disease

Belgium, France, Israel, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Lupus Arthritis

United States, Canada
Active Biotech AB

Completed

Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Denmark, Sweden
Teva Pharmaceutical Industries, Ltd.

Terminated

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Relapsing Remitting Multiple Sclerosis

Czechia, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, United Kingdom
Active Biotech AB

Completed

An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)

Systemic Sclerosis

Germany, Sweden, Switzerland
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Relapsing Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)

Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together

Pharmacokinetics | Pharmacodynamics

Germany
Active Biotech AB

Completed

A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

Healthy

Sweden
Active Biotech AB

Active, not recruiting

A Study of Laquinimod Eye-drops in Healthy Participants

Eye Diseases

Austria
Active Biotech AB

Completed

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Prostate Cancer

United States, Canada, Sweden
Active Biotech AB

Completed

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer

France, Poland, Ukraine, United Kingdom, United States, China, Germany, Taiwan, Spain, Belgium, Colombia, Israel, Bulgaria, India, Panama, Romania, Netherlands, Greece, Sweden, Korea, Republic of, Australia, Canada, Chile, New Zealand, ... and more
Ipsen

Terminated

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (TasQ003)

Prostatic Neoplasms, Castration-Resistant

China, Korea, Republic of, Taiwan
Facet Biotech

Completed

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Graft vs Host Disease

United States
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Ipsen

Completed

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Metastatic Renal Cell Cancer | Advanced or Metastatic Hepatocellular Cancer | Advanced or Metastatic Ovarian Cancer | Advanced or Metastatic Gastric Carcinoma

Belgium, Canada, France, Spain, United Kingdom
Ipsen

Terminated

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer

France, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Quan Dong Nguyen
Global Ophthalmic Research Center (GORC)

Recruiting

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (LION)

Inflammation | Uveitis

United States
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer (Radium-223)

Prostate Cancer | Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

United States
F2G Biotech GmbH
PRA Health Sciences

Completed

Absorption, Metabolism and Excretion of 14C-olorofim in Man (hAME)

Invasive Fungal Infections

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (BRAVO)

Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Merck Sharp & Dohme LLC

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
Teva Pharmaceuticals USA

Completed

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study

Healthy

Canada
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Azienda Ospedaliera V. Cervello

Unknown

Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies (IFNRIBAHE)

Hemoglobinopathies

Italy
University of Pennsylvania
Active Biotech AB

Recruiting

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Multiple Myeloma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

Lupus Nephritis

United States, Canada, France, Russian Federation, United Kingdom

Search clinical trials for: Laquinimod

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations